Related Experiment Videos
Failure to prevent decompression illness in rats by pretreatment with a soluble complement receptor
J R Broome1, R R Pearson, A J Dutka
1Naval Medical Research Institute, Bethesda, Maryland.
Summary
This study found that soluble complement receptor type 1 (sCR-1) did not reduce the incidence of decompression illness (DCI) in rats. Complement activation may not play a significant role in DCI development.
Area of Science:
- Physiology
- Biomedical research
- Diving medicine
Background:
- The role of complement activation in decompression illness (DCI) is debated.
- Intravascular gas bubbles may trigger complement activation, potentially influencing DCI susceptibility.
- Soluble complement receptor type 1 (sCR-1) is known to inhibit complement-dependent diseases.
Purpose of the Study:
- To investigate the effect of sCR-1 treatment on DCI incidence in a rat model.
- To determine if inhibiting complement activation impacts DCI development.
- To re-evaluate the correlation between DCI incidence and animal weight.
Main Methods:
- Rats were pre-treated with either sCR-1 or saline before undergoing a standardized decompression dive profile.
- The incidence of DCI was recorded and compared between the treatment and control groups.
- Body weight and DCI incidence were analyzed for correlation.
Main Results:
- No statistically significant difference in DCI incidence was observed between rats treated with sCR-1 and those treated with saline.
- The study failed to confirm a previously reported positive correlation between DCI incidence and increasing rat weight.
Conclusions:
- Pre-treatment with sCR-1 did not alter the incidence of DCI in this rat model.
- Complement activation may not be a primary factor in the pathogenesis of DCI.
- Further research is needed to elucidate the precise role of complement in DCI.